Ventyx biosciences announces initiation of dosing in a phase 2a trial of vtx3232 in patients with early parkinson's disease

San diego, sept. 06, 2024 (globe newswire) -- ventyx biosciences, inc. (nasdaq: vtyx) (“ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a phase 2a trial of vtx3232 in patients with early parkinson's disease.
VTYX Ratings Summary
VTYX Quant Ranking